Indication intelligence, analysis and sector perception

Sangamo Therapeutics (SGMO) closed its Biogen (BIIB) collaboration agreement

April 10, 2020 2:31pm

SGMO closed Thursday at $0.48 or +6.88% to $7.46

SGMO has received $225 million in stock proceeds; will receive additional $125 million upfront license fee by 5/8/2020

SGMO is also eligible to earn up to $2.37 billion in other development, regulatory and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1.445 billion in first commercial sale and other sales-based milestone payments

SGMO closed its previously announced sale of stock to Biogen (BIIB) and that the global licensing collaboration agreement for the development and commercialization of gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases is now effective.

Under the terms of the collaboration, Sangamo has received $225 million from the purchase by BIIB of newly issued SGMO stock and will receive an upfront license fee of $125 million from Biogen no later than May 8, 2020.

Sangamo is also eligible to earn tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.

The BOTTOM LINE: The “transaction exemplifies a strategy to partner assets when collaborator’s financial resources and clinical and therapeutic area expertise will enable more rapid development.” Adds a whole lot of “whoomph” to its last reported cash position of $362.47 million offset by debt of $44.41 million; also, might help “kill” the 14.26% short position

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.